Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: Association between tumor characteristics and survival outcome

Obstetrics and Gynecology

Volumn 125, Issue 2, 2015, Pages 424-433

  Matsuo, Koji ^a   Opper, Neisha R ^a   Ciccone, Marcia A ^a   Garcia, Jocelyn ^a   Tierney, Katherine E ^a   Baba, Tsukasa ^a   Muderspach, Laila I ^a   Roman, Lynda D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; GESTAGEN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ETHNICITY; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; WAIT TIME; BIOPSY; CANCER GRADING; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; UNITED STATES;

ADENOCARCINOMA; ADULT; BIOPSY; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; LOS ANGELES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84922452034     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000636     Document Type: Article

References (18)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
2. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther 2004; 4: 679-89
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-7
4. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet 2012; 379: 1352-60
5. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 2012; 126: 176-9
6. Elit LM, O'Leary EM, Pond GR, Seow HY. Impact of wait times on survival for women with uterine cancer. J Clin Oncol 2014; 32: 27-33
7. Pirog EC, Heller DS, Westhoff C. Endometrial adenocarcinoma-lack of correlation between treatment delay and tumor stage. Gynecol Oncol 1997; 67: 303-8
8. Menczer J, Krissi H, Chetrit A, Gaynor J, Lerner L, Ben-Baruch G, et al. The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. Am J Obstet Gynecol 1995; 173: 774-8
9. Levy T, Golan A, Menczer J. Endometrial endometrioid carcinoma: a glimpse at the natural course. Am J Obstet Gynecol 2006; 195: 454-7
10. Matsuo K, Yessaian AA, Lin YG, Pham HQ, Muderspach LI, Liebman HA, et al. Predictive model of venous thromboembolism in endometrial cancer. Gynecol Oncol 2013; 128: 544-51
11. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008; 108: 221-9
12. Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-A clinical and pathological evaluation. Gynecol Oncol 2012; 124: 15-20
13. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-9
14. Nagle CM, Francis JE, Nelson AE, Zorbas H, Luxford K, de Fazio A, et al. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2011; 29: 2253-8
15. Matsuo K, Whitman SA, Blake EA, Conturie CL, Ciccone MA, Jung CE, et al. Feto-maternal outcome of pregnancy complicated by vulvar cancer: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol 2014; 179: 216-23
16. Menczer J. Treatment delay in endometrial cancer. J Clin Oncol 2014; 32: 2113-4
17. Helpman L, Kupets R, Covens A, Saad RS, Khalifa MA, Ismiil N, et al. Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. Br J Cancer 2014; 110: 609-15
18. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73